Abstract
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC, which are all subjects to an extensive number of innovative drug candidates. This extensive 450+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been or are comparing different combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb' s Paraplatin (carboplatin) and Eli Lilly' s Gemzar (gemcitabine).
Table of Contents
1 Executive Summary
2 Methodologies
3 Table of Contents
- 3.1 List of Figures
- 3.2 List of Tables
- 3.3 List of Boxes
4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?
5 Antibody Drug Targets by Molecular Function
- 5.1 Carboxypeptidase Activity Targets
- 5.2 Catalytic Activity Targets
- 5.3 Cell Adhesion Molecule Activity Targets
- 5.4 Chaperone Activity Targets
- 5.5 Chemokine Activity Targets
- 5.6 Cofactor Binding Targets
- 5.7 Complement Activity Targets
- 5.8 Cytokine Activity Targets
- 5.9 DNA Topoisomerase Activity Targets
- 5.10 Extracellular Matrix Structural Constituent Targets
- 5.11 G-protein Coupled Receptor Activity Targets
- 5.12 Growth Factor Activity Targets
- 5.13 Hormone Activity Targets
- 5.14 Hydrolase Activity Targets
- 5.15 Intracellular Ligand-gated Ion Channel Activity Targets
- 5.16 Metallopeptidase Activity Targets
- 5.17 MHC Class I Receptor Activity Targets
- 5.18 Molecular Function Unknown Targets
- 5.19 Oxidoreductase Activity Targets
- 5.20 Peptide Hormone Targets
- 5.21 Protease Inhibitor Activity Targets
- 5.22 Protein Binding Targets
- 5.23 Receptor Activity Targets
- 5.24 Receptor Binding Targets
- 5.25 Receptor Signaling Complex Scaffold Activity Targets
- 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
- 5.27 RNA-directed DNA polymerase Activity Targets
- 5.28 Serine-type Peptidase Activity Targets
- 5.29 T Cell Receptor Activity Targets
- 5.30 Translation Regulator Activity Targets
- 5.31 Transmembrane Receptor Activity Targets
- 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 5.33 Transporter Activity Targets
- 5.34 Unclassified Targets
6 Antibody Drugs Targeting Signaling Pathways
- 6.1 Alpha6 Beta4 Integrin Signaling Pathway
- 6.1.1 Description of Pathway
- 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.2 Androgen Receptor Signaling Pathway
- 6.2.1 Description of Pathway
- 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.3 B Cell Receptor Signaling Pathway
- 6.3.1 Description of Pathway
- 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
- 6.4 EGFR1 Signaling Pathway
- 6.4.1 Description of Pathway
- 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.5 IL-2 Signaling Pathway
- 6.5.1 Description of Pathway
- 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
- 6.6 IL-4 Signaling Pathway
- 6.6.1 Description of Pathway
- 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
- 6.7 IL-6 Signaling Pathway
- 6.7.1 Description of Pathway
- 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.8 Kit Receptor Signaling Pathway
- 6.8.1 Description of Pathway
- 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.9 Notch Signaling Pathway
- 6.9.1 Description of Pathway
- 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.10 T Cell Receptor Signaling Pathway
- 6.10.1 Description of Pathway
- 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.11 TGF-beta Receptor Signaling Pathway
- 6.11.1 Description of Pathway
- 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
- 6.12 TNF-alpha Signaling Pathway
- 6.12.1 Description of Pathway
- 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
- 6.13 Wnt Signaling Pathway
- 6.13.1 Description of Pathway
- 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7 Antibodies Targeting Cancer Stem Cells
8 Targets of Antibody Conjugates
9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects
- 9.1 Anti-Angiogenesis
- 9.2 Apoptosis
- 9.3 Protein Kinase Inhibitors
10 Antibody Targets and Drugs by Cancer Indications
- 10.1 Basal Cell Cancer
- 10.2 Biliary Cancer
- 10.3 Bladder Cancer
- 10.4 Bone Cancer
- 10.5 Brain Cancer
- 10.6 Breast Cancer
- 10.7 Cervical Cancer
- 10.8 Cervical Dysplasia
- 10.9 Colorectal Cancer
- 10.10 Endometrial Cancer
- 10.11 Esophageal Cancer
- 10.12 Fallopian Tube Cancer
- 10.13 Gastrointestinal Cancers
- 10.14 Head and Neck Cancer
- 10.15 Leukemias
- 10.16 Liver Cancer
- 10.17 Lung Cancers
- 10.18 Lymphomas
- 10.19 Melanoma
- 10.20 Mesothelioma
- 10.21 Myelodysplastic syndrome
- 10.22 Myelomas
- 10.23 Nasopharyngeal Cancer
- 10.24 Oesophageal Cancer
- 10.25 Ovarian Cancer
- 10.26 Pancreatic Cancer
- 10.27 Peritoneal Cancer
- 10.28 Prostate Cancer
- 10.29 Renal Cancers
- 10.30 Sarcomas
- 10.31 Thyroid Cancer
11 Expression Profiles of Antibody Drug Targets
- 11.1 Human Tissues and Cancer Tissues
- 11.2 Cancer Lines and Cells
12 Lung cancer: An Introduction
- 12.1 Current Treatment Strategies
- 12.2 Disease Definition
- 12.3 Etiology & Pathophysiology
- 12.4 Prognosis
- 12.5 Epidemiology
13 Progress in Current Lung Cancer Treatment Strategies
- 13.1 Improvements Adding microtubule Inhibitor
- 13.2 Improvement of Disease Related Symptoms in Elderly Patients
- 13.3 Toxicity Profile Favored
- 13.4 A New Formula
- 13.5 Monotherapy?
- 13.6 Failed to Demonstrate a Survival Advantage
- 13.7 Reduction in Mortality Risk
14 Key Drug Strategies in Lung Cancer
- 14.1 Apoptosis
- 14.2 Antiangiogenesis and Antivascular Agents
- 14.2.1 EGFR and VEGFR as target
- 14.2.2 Immunotherapy
15 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline
- 15.1 Grade 4 Adverse Events
- 15.2 No New Remarks
- 15.3 No Significant Effect on Overall Survival
- 15.4 Bristol Myers Squibb Entered into an Agreement
- 15.5 Many Uncertainties Remain
- 15.6 Development Terminated
- 15.7 Continuing Enrollment
- 15.8 Apoptotic Inducer
- 15.9 Fully-Human Monoclonal Antibody
- 15.10 Eagerly Awaiting Data
- 15.11 Mutations and Response
- 15.12 Statistically and Clinically Significant Survival Advantage
- 15.13 Anti-Idiotypic Monoclonal Antibody
- 15.14 Shift in the Development Focus
- 15.15 Sensitizer
- 15.16 Treatment in Earlier-Stage Cancer Could be More Effective
- 15.17 Discontinued Radiosensitizer
- 15.18 Improvement in Chemoradiotherapy
- 15.19 Progress on HDAC Inhibitor
- 15.20 Progress Analysis Carboxyamidotriazole
- 15.22 Chemotherapy naïve subjects
16 Etiology and Pathophysiology of Melanoma
17 Current Melanoma Treatment Strategies
- 17.1 An Overview
- 17.2 Cytotoxic Drugs
- 17.2.1 Dacarbazine
- 17.2.2 Cisplatin
- 17.2.3 Carboplatin
- 17.2.4 Carmustine
- 17.2.5 Melphalan
- 17.2.6 Paclitaxel
- 17.2.7 Tamoxifen
- 17.2.8 Temozolomide
- 17.2.9 Vinblastine/Vinorelbine
- 17.3 Biological treatments
- 17.3.1 Intron A
- 17.3.2 Virulizin
- 17.3.3 Melacine
- 17.3.4 Alfanative (Multiferon)
- 17.3.5 Proleukin or (Macrolin)
- 17.3.6 Enhanzyn
- 17.3.7 M-VAX
- 17.4 Other
- 17.4.1 Ceplene Maxamine
18 Key Melanoma Therapy Strategies
- 18.1 Immunotherapy
- 18.2 Anti-angiogenesis
- 18.3 Apoptotic Induction
- 18.4 Gene Therapy
19 Current Melanoma Drug Development: Late Stage Pipeline
- 19.1 Immunotherapy
- 19.1.1 Oncophage
- 19.1.2 Canvaxin
- 19.1.3 GMK
- 19.1.4 MDX-010
- 19.1.5 OncoVax
- 19.1.6 ALLOVECTIN-7
- 19.1.7 Peginterferon alfa-2b
- 19.2 Anti-angiogenesis
- 19.2.1 Lenalidomide
- 19.3 Apoptotic Inducers
- 19.3.1 Genasense
- 19.4 Inhibiting Cell Growth
- 19.4.1 Temozolomide
20 Current Melanoma Drug Development: Early Stage Pipeline
- 20.1 Immunotherapy
- 20.1.1 INGN 241
- 20.1.2 QS-21
- 20.1.3 Talabostat
- 20.1.4 SB 249553
- 20.1.5 GVAX
- 20.1.6 GV 1001
- 20.1.7 Dexosome
- 20.1.8 Uvidem
- 20.1.9 NY-ESO-1 ISCOMS
- 20.1.10 NOVOVAC-M1
- 20.1.11 Oxxon Vaccine
- 20.1.12 Therion' s Melanoma Vaccine
- 20.1.13 ImmunoVex trimelan
- 20.1.14 OncoVEXGM-CSF
- 20.1.15 Zadaxin
- 20.1.16 Alvac-Mage1/Mage3
- 20.1.17 Iboctadekin
- 20.1.18 ProMune
- 20.1.19 BAY 504798
- 20.1.20 EMD 273063
- 20.2 Antiangiogenesis
- 20.2.1 Sorafenib
- 20.2.2 Vitaxin
- 20.2.3 Avastin
- 20.2.4 PI 88
- 20.3 Apoptotic Inducers
- 20.3.1 Didemnin B
- 20.3.2 KOS 953
- 20.4 Small Molecules Inhibiting Cell Growth
- 20.4.1 Pivanex
- 20.4.2 Karenitecin
- 20.4.3 Lomeguatrib
- 20.4.4 PD 0325901
- 20.4.5 SB 715992
- 20.4.6 INO 1001
- 20.4.7 CP 4055
- 20.5 Other Biological Drugs
- 20.5.1 AP 12009
- 20.5.2 Ecromeximab
- 20.5.3 ILX 651
- 20.5.4 Kahalalide F
- 20.5.5 ABX MA1
- 20.5.6 MJV 101
- 20.5.7 A Russian Melanoma Vaccine
- 20.5.8 Elea Vaccine
- 20.5.9 F 50040
21 Disclaimer
22 Appendix 1: Antibody Targets by Companies
23 Appendix 2. Treatment Guide Lines*
- 23.1 References
24 Appendix 3: Selected Company Profiles
- 24.1 Abgenix
- 24.2 Aphton
- 24.3 AstraZeneca
- 24.4 Bristol-Myers Squibb
- 24.5 Eli Lilly
- 24.6 Genentech
- 24.7 Genta
- 24.8 GlaxoSmithKline
- 24.9 ImClone
- 24.10 ISIS Pharmaceuticals
- 24.11 Ligand Pharmaceuticals
- 24.12 OSI Pharmaceuticals
- 24.13 Pfizer
- 24.14 Pharmacyclics
- 24.15 Sanofi- Aventis
- 24.16 Telik
25 Appendix 4 Progress profiles on approved drugs
- 25.1 Docetaxel
- 25.2 Vinorelbine
- 25.3 Gemcitabine
- 25.4 Paclitaxel
- 25.5 Pemetrexed
- 25.6 Gefitinib
- 25.7 Erlotinib
26 Appendix 4: Treatment Guide Lines Melanoma
27 Drug Index
28 Company Index
3.1 List of Figures
- Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)
- Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)
- Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)
- Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
- Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
- Figure 6: Pipeline Maturation of Catalytic Activity Targets
- Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target
- Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets
- Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target
- Figure 10: Pipeline Maturation of Chaperone Activity Targets
- Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target
- Figure 12: Pipeline Maturation of Chemokine Activity Targets
- Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target
- Figure 14: Pipeline Maturation of Cofactor Binding Targets
- Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target
- Figure 16: Pipeline Maturation of Complement Activity Targets
- Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target
- Figure 18: Pipeline Maturation of Cytokine Activity Targets
- Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target
- Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets
- Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target
- Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets
- Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target
- Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets
- Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target
- Figure 26: Pipeline Maturation of Growth Factor Activity Targets
- Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target
- Figure 28: Pipeline Maturation of Hormone Activity Targets
- Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target
- Figure 30: Pipeline Maturation of Hydrolase Activity Targets
- Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target
- Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets
- Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target
- Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets
- Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target63
- Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets
- Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target
- Figure 38: Pipeline Maturation of Molecular Function Unknown Targets
- Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target
- Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets
- Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target
- Figure 42: Pipeline Maturation of Peptide Hormone Targets
- Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target
- Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets
- Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target
- Figure 46: Pipeline Maturationof Protein Binding Targets
- Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target
- Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)
- Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)
- Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)
- Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)
- Figure 52: Pipeline Maturationof Receptor Binding Targets
- Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target
- Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets
- Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target
- Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
- Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target
- Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets
- Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target
- Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets
- Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target
- Figure 62: Pipeline Maturation of T cell Receptor Activity Targets
- Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target
- Figure 64: Pipeline Maturation of Translation Regulator Activity Targets
- Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target
- Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets
- Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target
- Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target
- Figure 70: Pipeline Maturation of Transporter Activity Targets
- Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target
- Figure 72: Pipeline Maturation of Unclassified Targets
- Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target
- Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology
- Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets
- Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target
3.2 List of Tables
- Table 1: Molecular Functions versus Oncology Antibody Drug Targets
- Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
- Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
- Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets
- Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets
- Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets
- Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets
- Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets
- Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets
- Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets
- Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets
- Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets
- Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets
- Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets
- Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets
- Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets
- Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets
- Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets
- Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets
- Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets
- Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets
- Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets
- Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets
- Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets
- Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets
- Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets
- Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets87
- Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets
- Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets
- Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets
- Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets
- Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets
- Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets
- Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets
- Table 36: Antibody Drugs Targeting Signaling Pathways
- Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets
- Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
- Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
- Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway
- Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway
- Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway
- Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway
- Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway
- Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway
- Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway
- Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway
- Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway
- Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway
- Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway
- Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway
- Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway
- Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway
- Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway
- Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway
- Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway
- Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway
- Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway
- Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway
- Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway
- Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway
- Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway
- Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway
- Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors
- Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal
- Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target
- Table 67: Immunoconjugated Antibody Pipeline According to Target
- Table 68: Antibodies in Oncology Reported to Affect Angiogenesis
- Table 69: Antibodies in Oncology Reported to Affect Apoptosis
- Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures
- Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors
- Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage
- Table 73: Antibody Pipeline by Targets in Basal Cell Cancer
- Table 74: Antibody Pipeline by Targets in Biliary Cancer
- Table 75: Antibody Pipeline by Targets in Bladder Cancer
- Table 76: Antibody Pipeline by Targets in Bone Cancer
- Table 77: Antibody Pipeline by Targets in Brain Cancer
- Table 78: Antibody Pipeline by Targets in Breast Cancer
- Table 79: Antibody Pipeline by Targets in Cervical Cancer
- Table 80: Antibody Pipeline by Targets in Cervical Dysplasia
- Table 81: Antibody Pipeline by Targets in Colorectal Cancer
- Table 82: Antibody Pipeline by Targets in Endometrial Cancer
- Table 83: Antibody Pipeline by Targets in Esophageal Cancer
- Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer
- Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers
- Table 86: Antibody Pipeline by Targets in Head and Neck Cancer
- Table 87: Antibody Pipeline by Targets in Leukemias
- Table 88: Antibody Pipeline by Targets in Liver Cancer
- Table 89: Antibody Pipeline by Targets in Lung Cancers
- Table 90: Antibody Pipeline by Targets in Lymphomas
- Table 91: Antibody Pipeline by Targets in Melanoma
- Table 92: Antibody Pipeline by Targets in Mesothelioma
- Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome
- Table 94: Antibody Pipeline by Targets in Myelomas
- Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer
- Table 96: Antibody Pipeline by Targets in Oesophageal Cancer
- Table 97: Antibody Pipeline by Targets in Ovarian Cancer
- Table 98: Antibody Pipeline by Targets in Pancreatic Cancer
- Table 99: Antibody Pipeline by Targets in Peritoneal Cancer
- Table 100: Antibody Pipeline by Targets in Prostate Cancer
- Table 101: Antibody Pipeline by Targets in Renal Cancers
- Table 102: Antibody Pipeline by Targets in Sarcomas
- Table 103: Antibody Pipeline by Targets in Thyroid Cancer
- Table 104: Expression Profiles of Antibody Drug Targets in Oncology
- Table 1: Chemotherapeutic drugs for treatment of NSCLC
- Table 2. Near Term Approved Drugs for the Treatment of NSCLC
- Table 3: Chemotherapy Drugs off Patent
- Table 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
- Table 5: VTA agents under development
- Table 6: EGFR or VEGFR inhibitors
- Table 7: FMS-like tyrosine kinases and their Synonyms
- Table 8: Fms-related Tyrosine Kinase Targets in Development
- Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
- Table 10: Cancer immunotherapy strategies
- Table 11: Recently presented studies Lapatinib
- Table 12: Recently presented studies ZD-6474
- Table 13: Recently presented studies vinflunine
- Table 14: Recently presented studies Panitumumab
- Table 15: Recently presented studies Genasense
- Table 16: Recently presented studies cetuximab
- Table 17: Recently presented studies bevacizumab
- Table 18: Recently presented studies bexarotene
- Table 19: Recently presented studies Xcytrin
- Table 1: Critical Risk Factors for Development of Melanoma
- Table 2: Definition and Description of Stages of Melanoma
- Table 3: Prognosis of the 4 Stages of Malignant Melanoma
- Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
- Table 5: Progress Profile Dacarbazine
- Table 6: Progress Profile Cisplatin
- Table 7: Progress Profile Carboplatin
- Table 8: Progress Profile Carmustine
- Table 9: Progress Profile Melphalan
- Table 10: Progress Profile Paclitaxel
- Table 11: Progress Profile Tamoxifen
- Table 12: Progress Profile Temozolomide
- Table 13: Progress Profile Vinblastine/Vinorelbine
- Table 14: Progress Profile Interferon alfa-2b
- Table 15: Development Milestones- Virulizin
- Table 16: Development Milestones - Melacine
- Table 17: Development Milestones - Alfanative
- Table 18: Development Milestones - Proleukin
- Table 19: Deployed Strategies for Blocking Angiogenesis
- Table 20: Phase III Randomized Studies of Melanoma Vaccines.
- Table 21: Tumor antigen based vaccines
- Table 22: In vivo Gene Therapy
- Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
- Table 24: Ex vivo gene therapy loading of antigen presenting cells
- Table 25: Overview of Immunostimulants in Development based on Type
- Table 26: Overview of Immuno-Biologicals
- Table 27: Overview of Gene Therapy Drugs for Immunostimulation
- Table 28: MDX-010' s Collaborative History and Landscape
- Table 29: Anti-angiogenisis Drugs under Development
- Table 30: Overview Apoptopic Inducer Drugs
- Table 31: Overview of Small Molecule Drugs
- Table 32: Selected Regulatory Progress of Sorafenib
- Table 33: Selected Regulatory Progress of Didemin B
- Table 34: Overview of Various Biological Drugs in Development for Melanoma
3.3 List of Boxes
- Box 1: Quick facts on Docetaxel
- Box 2: Scientific Data on Docetaxel
- Box 3: Quick Facts - Vinorelbine
- Box 4: Scientific Data on Vinorelbine
- Box 5: Quick Facts - Gemcitabine
- Box 6: Scientific Data on gemcitabine
- Box 8: Quick Facts - pemetrexed
- Box 7: Scientific Data on Pemetrexed
- Box 9: Quick Facts - Gefitinib
- Box 10: Scientific Data on Gefitinib
- Box 11: Quick Facts - Erlotinib
- Box 1: Quick Facts - Enhanzyn
- Box 2: Quick Facts - M-VAX
- Box 3: M-VAX - Business & Market Bakground
- Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
- Box 5: Introgen' s INGN 241 Shows Vaccine Properties
- Box 6: Quick Facts - Oncophage
- Box 7: Oncophage - Designation and Status
- Box 8: Quick Facts - Canvaxin
- Box 9: Canvaxin - Designation and Status
- Box 10: CancerVax Milestone payment
- Box 11: Quick Facts - GM2-KLH Vaccine
- Box 12: Progenics Reaquires Rights to Vaccine
- Box 13: Completed Melanoma Phase III trials
- Box 14: Quick Facts - MDX-010
- Box 15: Quick Facts -OncoVax
- Box 16: Quick Facts - ALLOVECTIN-7
- Box 17: Quick Facts - Peginterferon alfa-2b
- Box 18: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
- Box 19: Quick Facts - Lenalidomide
- Box 20: Quick Facts - Oblimersen
- Box 21: Quick Facts - Temozomide
- Box 22: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
- Box 23: Regulatory Progress
- Box 24: Quick Facts - INGN 241
- Box 25: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
- Box 26: Quick Facts - QS-21
- Box 27: Quick Facts - Talabostat
- Box 28: Quick Facts - SB 249553
- Box 29: Quick Facts - GVAX
- Box 30: Agreement Japan Tobacco and Cell Genesys
- Box 31: Predicted launch of GVAX
- Box 32: Quick Facts - GV 1001
- Box 33: Quick Facts - Dexosome
- Box 34: Important Milestones and License Fees
- Box 35: Quick Facts - Uvidem
- Box 36: Agreements Between Sanofi-Aventis and IDM
- Box 37: Quick Facts - NY-ESO-1 ISCOMS
- Box 38: NY-ESO-1 and ISCOMATRIX
- Box 39: Quick Facts - NovoVac-M1
- Box 40: Quick Facts - Oxxon vaccine
- Box 41: Quick Facts - Therion' s Melanoma Vaccine
- Box 42: Quick Facts - ImmunoVEX trimelan
- Box 43: Quick Facts - OncoVEX GM-CSF
- Box 44: Quick Facts - ZADAXIN
- Box 45: Developmental History Thymosin alpha1
- Box 46: Quick Facts - Alvac-Mage1/Mage3
- Box 47: Quick Facts - iboctadekin
- Box 48: Quick Facts - PF-3512676
- Box 49: Quick Facts - BAY-504798
- Box 50: Quick Facts - EMD-273063
- Box 51: Quick Facts - Sorefenib
- Box 52: Quick Facts - Vitaxin
- Box 53: Quick Facts . Bevacizumab
- Box 54: Quick Facts - PI88
- Box 55: Quick Facts - Didemnin B
- Box 56: Quick Facts - KOS 953
- Box 57: Quick Facts - Pivanex
- Box 58: Quick Facts - Karenitecin
- Box 59: Company Statement
- Box 60: Quick Facts - Lomeguatrib
- Box 61: Quick Facts - PD 0325901
- Box 62: Quick Facts - SB 715992
- Box 63: Quick Facts - INO 1001
- Box 64: Quick Facts - CP 4055
- Box 65: Quick Facts - AP 12009
- Box 66: Quick Facts - Ecromeximab
- Box 67: Quick Facts - ILX 651
- Box 68: Quick Facts - Kahalalide F
- Box 69: Quick Facts - ABX MA1
- Box 70: Quick Facts - MJV 101
- Box 71: Quick Facts - Russian Melanoma Vaccine
- Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
- Box 73: Quick Facts - F 50040
- Box 74: KpOmpA Technology
